InflaRx (IFRX) Competitors

Benitec Biopharma (NASDAQ:BNTC) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings, community ranking and analyst recommendations.

Does the media refer more to BNTC or IFRX?

In the previous week, InflaRx had 9 more articles in the media than Benitec Biopharma. MarketBeat recorded 12 mentions for InflaRx and 3 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.56 beat InflaRx's score of 0.56 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Benitec Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is BNTC or IFRX more profitable?

Benitec Biopharma has a net margin of 0.00% compared to InflaRx's net margin of -33,362.70%. Benitec Biopharma's return on equity of -44.61% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-44.61%	-41.25%
InflaRx	-33,362.70%	-65.98%	-56.86%

Do analysts rate BNTC or IFRX?

Benitec Biopharma currently has a consensus target price of $24.71, suggesting a potential upside of 63.18%. InflaRx has a consensus target price of $9.33, suggesting a potential upside of 436.40%. Given InflaRx's higher probable upside, analysts plainly believe InflaRx is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.22
InflaRx	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals have more ownership in BNTC or IFRX?

52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 1.3% of Benitec Biopharma shares are held by insiders. Comparatively, 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Does the MarketBeat Community prefer BNTC or IFRX?

InflaRx received 46 more outperform votes than Benitec Biopharma when rated by MarketBeat users. However, 65.67% of users gave Benitec Biopharma an outperform vote while only 65.15% of users gave InflaRx an outperform vote.

Company	Underperform	Outperform
Benitec Biopharma	Outperform Votes 197 65.67%	Underperform Votes 103 34.33%
InflaRx	Outperform Votes 243 65.15%	Underperform Votes 130 34.85%

Which has better earnings and valuation, BNTC or IFRX?

Benitec Biopharma has higher earnings, but lower revenue than InflaRx. Benitec Biopharma is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	$80K	4,439.57	-$21.75M	-$1.51	-10.03
InflaRx	$165.79K	704.58	-$46.18M	-$0.87	-2.00

Which has more risk & volatility, BNTC or IFRX?

Benitec Biopharma has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, InflaRx has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500.

Summary

Benitec Biopharma beats InflaRx on 11 of the 19 factors compared between the two stocks.